MedTrace Logo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

NCT02140320 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2015-04-14

No results posted yet for this study

Summary

RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).

The objective of this study is to investigate the safety, tolerability and pharmacokinetics of single doses of RV1729 and repeat doses of RV1729 for up to 28 days.

Conditions

Interventions

DRUG

RV1729 single dose

Safety and tolerability of single dose

DRUG

RV1729 matching placebo single dose

Safety and tolerability of single dose

DRUG

RV1729 14 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 matching placebo 14 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 28 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 matching placebo 28 day repeat dose

Safety and tolerability of repeat doses

Sponsors & Collaborators

  • Respivert Ltd

    lead INDUSTRY

Principal Investigators

  • Liza O'Dowd, MD · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140320 on ClinicalTrials.gov